Sana Biotechnology
Executive Vice President and Global Head of Research and Development
Juno Therapeutics Apr 2017 - May 2018
President of Research and Development
Sofinnova Sep 2016 - Mar 2017
Partner
Ultragenyx Pharmaceutical Inc. Jul 2014 - Aug 2016
Chief Medical Officer and Executive Vice President
Myokardia Jul 2014 - Aug 2016
Member Board of Directors
Education:
Tufts University School of Medicine 1992 - 1996
Doctor of Medicine, Doctorates
Cornell University 1988 - 1992
Bachelors, Bachelor of Science
N.c.jindal Public School
Bachelors
Skills:
Pharmaceutical Industry Biotechnology Immunology Clinical Development Infectious Diseases Clinical Trials Biopharmaceuticals Drug Development Oncology Neuroscience Life Sciences Lifesciences Medicine Gcp
The present application describes therapy with angiogenesis antagonists such as anti-VEGF antibodies. In particular, the application describes the use of such antagonists to treat autoimmune disease in a patient who has failed prior treatment such as treatment with DMARDs or TNFα-inhibitors.
Mark Totoritis - Rancho Santa Fe CA, US Timothy Mark Shaw - Hertfordshire, GB Sunil Agarwal - Corte Madera CA, US David Yocum - San Mateo CA, US Ariella Kelman - Hillsborough CA, US
International Classification:
A61K 39/395 A61P 19/02 A61P 37/00 A61B 10/00
US Classification:
424 92, 4241331
Abstract:
Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.
Database System With Improved Methods For Updating Records
Sunil Agarwal - Alameda CA Vasudha Krishnaswamy - Redwood City CA
Assignee:
Sybase, Inc. - Emeryville CA
International Classification:
G06F 1730
US Classification:
707 2
Abstract:
Database system and methods are described for updating records, such as are commonly used in a relational database environment. Updates are carried out in a manner which allows a substantial portion of the work to be performed in direct mode (when possible), thereby avoiding the inefficiency of re-reading records. In this fashion, a scenario which requires deferred updating can, in accordance with the present invention, be treated mostly as a direct update, with minimal deferred updating. Given a query involving an "unsafe" unique index (i. e. , query includes update to key field), for instance, the present invention provides a method whereby each data row is updated in direct mode. In conjunction with this, the corresponding index row is deleted in direct mode. The system will not insert an index row at this point, however.
I wake and I'm one person and when I go to sleep I know for certain I'm somebody else I don't know who I am most of the time. Its like you got yesterday today tommorow all in the same room....THERE'S NO TELLING WHAT CAN HAPPEN........
Ultragenyx Pharma (NASDAQ: RARE) 3.8% LOWER; disclosed in an SEC filing: On June 10, 2016, Sunil Agarwal gave notice of his intention to resign as Executive Vice President and Chief Medical Officer of Ultragenyx Pharmaceutical Inc. (the Company) to pursue an alternative career path. Dr. Agarwals
Date: Jun 17, 2016
Category: Business
Source: Google
Rheumatoid Arthritis Drugs Square Off Against Humira
Roche hopes doctors will steer more arthritis patients to Actemra if they struggle with methotrexate, rather than advising them to use Humira alone. These data will be informative to physicians, Sunil Agarwal, head of Roches immunology and infectious diseases section, tells the Health Blog. The h